title: Preventive effects of jujube polysaccharides on fructose-induced insulin resistance and dyslipidemia in mice.
abstract: High fructose intake is associated with adverse metabolic syndromes. This study was designed to investigate whether the polysaccharides derived from Zizyphus jujube cv. Shaanbeitanzao (ZSP) could alleviate high fructose-induced insulin resistance and dyslipidemia in mice. ZSP was identified by capillary zone electrophoresis as an acidic heteropolysaccharide with l-arabinose, d-galactose and d-galacturonic acid being the main component monosaccharides. Mice were provided with 20% high-fructose water and ZSP was administered intragastrically at doses of 0, 200 or 400 mg kg(-1) BW for 4 weeks. Fructose-treated mice showed hyperglycemia, hyperinsulinemia and dyslipidemia with impaired insulin sensitivity (p < 0.05). Administration of ZSP at a dose of 400 mg kg(-1) BW significantly reduced the serum levels of glucose, insulin, TC, TG, LDL-C, and VLDL-C (p < 0.01). ZSP also markedly improved the HDL-C level, homeostasis model assessment for insulin resistance (HOMA-IR) and β-cell function (HOMA-β), and decreased the atherogenic index (AI) of the mice exposed to high-fructose water. Histopathological test with H&E and oil red O staining confirmed liver steatosis induced by a high-fructose diet and the hepatoprotective effect of ZSP. These findings indicate that the jujube polysaccharides may ameliorate insulin resistance and dyslipidemia in fructose-treated mice.
authors.affiliation: School of Pharmacy, Fourth Military Medical University, Xi'an 710032, China. yanzhao@fmmu.edu.cn.
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhao
authors.forename: Xingbin
authors.initials: X
authors.lastname: Yang
authors.forename: Daoyuan
authors.initials: D
authors.lastname: Ren
authors.forename: Dongying
authors.initials: D
authors.lastname: Wang
authors.forename: Yang
authors.initials: Y
authors.lastname: Xuan
mesh_terms: D000818:Animals; D001089:Arabinose / Q000378:metabolism; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004305:Dose-Response Relationship, Drug; D050171:Dyslipidemias / Q000517:prevention & control*; D005234:Fatty Liver / Q000188:drug therapy; D005632:Fructose / Q000009:adverse effects; D005690:Galactose / Q000378:metabolism; D006603:Hexuronic Acids / Q000378:metabolism; D006943:Hyperglycemia / Q000188:drug therapy; D006946:Hyperinsulinism / Q000188:drug therapy; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D050417:Insulin-Secreting Cells / Q000378:metabolism; D008297:Male; D051379:Mice; D010936:Plant Extracts / Q000494:pharmacology*; D011134:Polysaccharides / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood; D031957:Ziziphus / Q000737:chemistry*
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D006603:Hexuronic Acids; D007328:Insulin; D010936:Plant Extracts; D011134:Polysaccharides; D014280:Triglycerides; D005632:Fructose; C007819:galacturonic acid; D001089:Arabinose; D005690:Galactose